

RETRACTION NOTE

Open Access



Retraction Note: Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies

Edward Rockenstein¹, Kiren Ubhi¹, Michael Mante¹, Jazmin Florio¹, Anthony Adame¹, Stefan Winter², Hemma Brandstaetter², Dieter Meier² and Eliezer Masliah^{1,3*}

Retraction Note:

The Editor has retracted this article because of concerns regarding figures presented in this work. These concerns call into question the article's overall scientific soundness. An investigation conducted after its publication discovered the following issues:

- A portion of the right half of Panel *3RTau mut tg, Vehicle | Dentate* in Fig. 1a appears to overlap, when horizontally flipped, with a portion of the right half of Panel *3RTau mut tg, Cerebrolysin | Dentate* in the same figure. These Panels represent tissues taken from animals which underwent different treatments;
- A portion of the left half of Panel *Non-tg, Vehicle | Dentate gyrus* in Fig. 2a appears to overlap with a portion of the right half of Panel *Non-tg, Cerebrolysin | Dentate gyrus* in the same figure. These Panels represent tissues taken from animals which underwent different treatments;
- A portion of Panel *Non-tg, Vehicle | Neocortex* in Fig. 2a appears to overlap when re-scaled, with Panel *Non-tg, Cerebrolysin | Neocortex* in Fig. 2c. These Panels represent tissues taken from animals which underwent different treatments;
- A portion of Panel *Non-tg, Cerebrolysin | Neocortex* in Fig. 2a appears to overlap, when re-scaled, with a portion of the right half of Panel *Non-tg, Vehicle | Neocortex* in Fig. 2c. These Panels represent tissues taken from animals which underwent different treatments;
- A portion of the left half of Panel *Non-tg, Cerebrolysin | MPA2, 3–6 mo.* in Fig. 4e appears to overlap, when re-scaled, with a portion of the left half of Panel *3RTau mut tg, Cerebrolysin | MPA2, 3–6 mo.* in the same figure. These Panels represent tissues taken from animals subject to different experimental conditions.

The online version of the original article can be found at <https://doi.org/10.1186/s12868-015-0218-7>

*Correspondence:

Eliezer Masliah
emasliah@ucsd.edu

¹Department of Neurosciences, University of California, La Jolla, San Diego, CA 92093-0624, USA

²Clinical Research and Pharmacology, EVER Neuro Pharma GmbH, Unterach, Austria

³Department of Pathology, University of California, La Jolla, San Diego, CA, USA

The Editor therefore no longer has confidence in the integrity of the research presented in this article.

The authors have not replied to correspondence from the Publisher about this retraction. The Publisher has been informed that Edward Rockenstein has passed away. Published online: 10 March 2025

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.